


Supplemental Figure 1. c-CBL is over-expressed in CTCL.

a. Immunoblot shows that relative to normal CD4⁺ blood T cells (N1), 3/4 additional SS blood samples (P11,13,14) expressed more than 3-fold greater c-CBL protein levels. MyLa (M). GAPDH is loading control.

b. Immunoperoxidase stained paraffin sections show that relative to T cells in reactive tonsil control (1), increased c-CBL expression is present in patch/plaque MF (2), tumor MF (3) and SS erythroderma (4). Methylene blue counterstain. Bar = 50 microns.

c. Quantitative multispectral image analysis shows that relative to reactive tonsil controls (N=3), expression of c-CBL in-situ is about 3 fold greater in patch/plaque MF (N=10), tumor MF (N=3) and SS erythroderma (N=2).

Y axis: relative optical density (OD) units. * p<0.005.



Supplemental Figure 2. MTX induces minimal alterations in c-CBL expression.

a. Quantitative RT/PCR shows no significant difference in c-CBL transcript levels after MTX treatment of CTCL lines (MyLa, Hut-78, HH, SZ4, SeAx) or SS primary leukemic samples (P1, P2, P15). Paired bars represent DMSO control and MTX.

b. Immunoblot of CTCL lines HH, MyLa and Hut-78 show only minimal reductions in c-CBL protein levels after treatment with MTX. DMSO control (D) c-CBL level set as 1. MTX (M). All values normalized to beta-actin loading control.